Literature DB >> 35391631

Evolution of serum progesterone levels in the very early luteal phase of stimulated IVF/ICSI cycles post hCG trigger: a proof of concept study.

Carol Coughlan1,2, R Vitorino3, L Melado3, S Digma3, J Sibal3, R Patel3, B Lawrenz3,4, H Fatemi3.   

Abstract

BACKGROUND: Studies have suggested that controlled ovarian hyperstimulation adversely affects endometrial receptivity due to advanced endometrial maturation. This adverse effect is mainly attributed to supraphysiological levels of both estrogen and progesterone identified in stimulated cycles. There is a paucity of published data investigating the very early luteal steroid profile following hCG trigger. AIM OF THE STUDY: This prospective, observational study was undertaken to determine the increase in serum progesterone levels after human chorionic gonadotrophin (hCG) trigger in stimulated IVF/ICSI cycles.
MATERIALS AND METHODS: This proof-of-concept study included 11 patients requiring ovarian stimulation for IVF/ICSI and who planned to avail of pre-implantation genetic screening with embryo vitrification of their biopsied embryos at blastocyst stage. For each study participant, five additional blood samples were drawn at the following specific times in the stimulation cycle, on the morning (10.00-12.00) of the assigned day to induce final oocyte maturation with hCG trigger, immediately prior to administration of hCG for final oocyte maturation, 1 h, 2 h, and 36 h post hCG trigger. A prediction model, the Gompertz curve, was used to determine serum progesterone levels at intervals between the 2 h post hCG trigger sample and the day of oocyte retrieval.
RESULTS: Statistically significant increases in serum progesterone levels were identified following hCG administration as early as 1 h following trigger (P4 0.57 ng/ml, p < 0.05), 2 h following trigger (P4 0.88 ng/ml, p < 0.001) and on the day of oocyte retrieval (P4 9.68 ng/ml, p < 0.001). According to our prediction model, the Gompertz curve, the projected serum progesterone level at 4 h post trigger would have achieved a level of 1.45 ng/ml, 8 h post trigger of 3.04 ng/ml, and 12 h post trigger of 4.8 ng/ml. The very early and significant increases in serum progesterone following hCG trigger are clearly demonstrated in this study.
CONCLUSION: The endometrium is undoubtedly exposed to rapidly increasing serum progesterone levels post hCG trigger that would not be identified until much later in natural menstrual cycles. TRIAL REGISTRATION NUMBER: This study is registered with clinicaltrials.gov under the identifier NCT04417569.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Endometrium; IVF, in-vitro fertilization; Progesterone; hCG, Human chorionic gonadotrophin

Mesh:

Substances:

Year:  2022        PMID: 35391631      PMCID: PMC9107532          DOI: 10.1007/s10815-022-02474-4

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.357


  39 in total

1.  Biopsy studies of human endometrium: criteria of dating and information about amenorrhea, menorrhagia, and time of ovulation.

Authors:  J Rock; M K Bartlett
Journal:  J Am Med Assoc       Date:  1937-06-12

2.  Effect of ovarian stimulation with recombinant follicle-stimulating hormone, gonadotropin releasing hormone antagonists, and human chorionic gonadotropin on endometrial maturation on the day of oocyte pick-up.

Authors:  Efstratios Kolibianakis; Claire Bourgain; Carola Albano; Kaan Osmanagaoglu; Johan Smitz; Andre Van Steirteghem; Paul Devroey
Journal:  Fertil Steril       Date:  2002-11       Impact factor: 7.329

3.  Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone-gonadotropin-releasing hormone antagonist in vitro fertilization cycles.

Authors:  Human M Fatemi; Nikolaos P Polyzos; Inge van Vaerenbergh; Claire Bourgain; Christophe Blockeel; Birgit Alsbjerg; Evangelos G Papanikolaou; Peter Humaidan
Journal:  Fertil Steril       Date:  2013-06-24       Impact factor: 7.329

4.  The luteal phase of cycles utilizing controlled ovarian hyperstimulation and the possible impact of this hyperstimulation on embryo implantation.

Authors:  B A Kolb; R J Paulson
Journal:  Am J Obstet Gynecol       Date:  1997-06       Impact factor: 8.661

Review 5.  Hormonal control of endometrial receptivity. The egg donation model and controlled ovarian hyperstimulation.

Authors:  D De Ziegler; R Fanchin; M Massonneau; C Bergeron; R Frydman; P Bouchard
Journal:  Ann N Y Acad Sci       Date:  1994-09-30       Impact factor: 5.691

6.  Comparison of luteal phase profile in gonadotrophin stimulated cycles with or without a gonadotrophin-releasing hormone antagonist.

Authors:  G Ragni; W Vegetti; E Baroni; M Colombo; M Arnoldi; G Lombroso; P G Crosignani
Journal:  Hum Reprod       Date:  2001-11       Impact factor: 6.918

7.  Premature elevation of plasma progesterone alters pregnancy rates of in vitro fertilization and embryo transfer.

Authors:  R Fanchin; D de Ziegler; J Taieb; A Hazout; R Frydman
Journal:  Fertil Steril       Date:  1993-05       Impact factor: 7.329

8.  Endometrial evaluation by aspiration biopsy on the day of oocyte retrieval in the embryo transfer cycles in patients with serum progesterone rise during the follicular phase.

Authors:  F Ubaldi; C Bourgain; H Tournaye; J Smitz; A Van Steirteghem; P Devroey
Journal:  Fertil Steril       Date:  1997-03       Impact factor: 7.329

9.  The early luteal hormonal profile in IVF patients triggered with hCG.

Authors:  Lan N Vuong; Tuong M Ho; Toan D Pham; Vu N A Ho; Claus Yding Andersen; Peter Humaidan
Journal:  Hum Reprod       Date:  2020-01-01       Impact factor: 6.918

10.  Too much of a good thing? Experimental evidence suggests prolonged exposure to hCG is detrimental to endometrial receptivity.

Authors:  Jemma Evans; Lois A Salamonsen
Journal:  Hum Reprod       Date:  2013-03-20       Impact factor: 6.918

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.